Cargando…
Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have gained momentum as the latest class of antidiabetic agents for improving glycemic control. Large-scale clinical trials have reported that SGLT2 inhibitors reduced cardiovascular outcomes, especially hospitalization for heart failure in patients...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462040/ https://www.ncbi.nlm.nih.gov/pubmed/34621491 http://dx.doi.org/10.4330/wjc.v13.i9.464 |